BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SOFIE - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://sofie.com
X-WR-CALDESC:Events for SOFIE
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220608T153000
DTEND;TZID=America/New_York:20220608T163000
DTSTAMP:20260408T180824
CREATED:20220601T234639Z
LAST-MODIFIED:20220601T235001Z
UID:2309-1654702200-1654705800@sofie.com
SUMMARY:Fibroblast Activation Protein (FAP) - A promising target for radiopharmaceuticals
DESCRIPTION:Presenter: Sherly Mosessian\, Ph.D\nSOFIE Chief Scientific Officer \nDr. Mosessian earned her bachelors degree in Biochemistry\, followed by her Ph.D from UCLA Department of Molecular\, Medical Pharmacology\, with publications in tumor signaling\, molecular imaging targets and clinical trials of Position Emission Tomography (PET) probes. In her role as the Chief Scientific Officer of SOFIE she formulates the strategic plan for scientific objectives of the organization\, including leading the FAPI clinical development program. \nDate: June 8\, 2022\nTime: 3:30pm EDT \nRegister Now\nWho should attend? PET Interpreters\, Technologists\, Referring Physicians\, Marketers \nIn this webinar\, Dr. Mosessian will: \n\nExplain what is FAP and what role it plays in oncology\nIdentify key radiopharmaceuticals involved in FAP targeting\nDescribe the current state of clincal development for FAP Inhibitors (FAPI)
URL:https://sofie.com/event/fibroblast-activation-protein-fap-a-promising-target-for-radiopharmaceuticals/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2021/09/webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220611
DTEND;VALUE=DATE:20220615
DTSTAMP:20260408T180824
CREATED:20220515T025622Z
LAST-MODIFIED:20220526T152221Z
UID:2292-1654905600-1655251199@sofie.com
SUMMARY:SNMMI Annual Meeting 2022
DESCRIPTION:The SNMMI 2022 Annual Meeting is recognized as the premier educational\, scientific\, research\, and networking event in nuclear medicine and molecular imaging. The four day event\, taking place each June\, provides physicians\, technologists\, pharmacists\, laboratory professionals\, and scientists with an in-depth view of the latest research and development in the field as well as providing insights into practical applications for the clinic. \nVisit SOFIE at the upcoming meeting from June 11 – 14\, 2022 in Vancouver\, Canada at Booth #319. \nFAP Satellite Symposium at SNMMI – Sunday\, June 12\, 2022 from 6:30–8:30 pm PDTLearn more \nContact us to learn more about the FAP User Meeting.
URL:https://sofie.com/event/snmmi-annual-meeting-2022/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/05/Vancouver.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220825
DTEND;VALUE=DATE:20220826
DTSTAMP:20260408T180824
CREATED:20220815T215614Z
LAST-MODIFIED:20220815T215739Z
UID:2632-1661385600-1661471999@sofie.com
SUMMARY:PET Radiation Safety: The New Radiopharms on the Block
DESCRIPTION:Presenter: Kimon Jackson\, MSMP\, MSA\, CNMT\nClinical Account Executive for SOFIE \nA Nuclear Medicine Technologist with 20+ years of imaging experience. Kimon worked as a Nuclear Medicine/PET Supervisor for 12 years while serving as the Nuclear Medicine/PET health system resource. She went back to school earning a Master of Science in Healthcare Administration and Master of Science in Medical Physics. She has also worked as a health system Medical Physicist and Radiation Safety Officer for four years and taught Radiation Safety as adjunct faculty at the ODU Nuclear Medicine program for seven years. Kimon\, provided Radiation Safety in-services to various students\, technologists\, physicians\, and support staff. She also provided a credited Radiation Safety talk to the Virginia Association of Vascular and Interventional Radiographers (AVIR) chapter. Kimon currently is the Mid Atlantic CAE at SOFIE.  \nDate: August 25\, 2022\nTime: 3:30pm EST \nRegister Now\nWho should attend? PET Interpreters\, Technologists\, Referring Physicians\, Marketers \nIn this webinar\, Ms. Jackson will: \n\nIdentify the “new” PET radiopharmaceuticals\nProvide an overview of the physics of the “new” isotopes\nReview of partial volume effect\nDiscuss radiation safety concepts for the PET environment
URL:https://sofie.com/event/pet-radiation-safety-the-new-radiopharms-on-the-block/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2021/09/webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220928
DTEND;VALUE=DATE:20221002
DTSTAMP:20260408T180824
CREATED:20220907T185644Z
LAST-MODIFIED:20220916T220618Z
UID:2650-1664323200-1664668799@sofie.com
SUMMARY:World Molecular Imaging Congress
DESCRIPTION:Visit SOFIE at Booth #203 at the upcoming meeting from September 28 – October 1\, 2022 in Miami\, FL. We will also be sponsoring Educational Session 3: Molecular Imaging – Nuclear \n\n\n\n Wednesday\, September 28\, 2022\n 1:30 PM – 3:00 PM\n 242/243\n Education\n\n\n\n\n\nLearning Objectives\n\nRecognize recently developed hybrid imaging methods currently being used in the field.\nAnalyze the various modalities of MI\, such as optical ultrasound\, magnetic resonance imaging (MRI)\, and nuclear medicine\, and compare and contrast the advantages and limits of each.\nRecognize the common concepts that underlie molecular imaging probes for each of the various imaging modalities\, as well as the possibility of multi-modality probes.\nIdentify Molecular Imaging applications and correlate them with the methodologies and probes that have been employed in preclinical and clinical scenarios.\nRecognize the possibilities\, benefits\, and shortcomings of specialized molecular imaging for preclinical\, clinical\, and translational research.\n\nLearn more
URL:https://sofie.com/event/world-molecular-imaging-congress/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/09/Miami.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221027T153000
DTEND;TZID=America/New_York:20221027T163000
DTSTAMP:20260408T180824
CREATED:20221026T185426Z
LAST-MODIFIED:20221026T185640Z
UID:2813-1666884600-1666888200@sofie.com
SUMMARY:Breast Cancer PET/CT Applications Webinar
DESCRIPTION:Presenter: Dr. Robert Bridwell\, MD\, MBA Medical Advisor at SOFIE Dr. Robert Bridwell\, medical advisor to SOFIE\, and co-founder of PETLinQ\, is a board-certified physician in both Internal Medicine and Nuclear Medicine. He has extensive knowledge and experience in continuous quality improvement programs for PET and PET/CT imaging\, utilizing physician empowerment training\, protocol development assistance\, and quality assurance guidelines. In the last five years\, Dr. Bridwell has been invited to make numerous presentations\, which have included more than 1200 hours of CME credit delivered to more than 350 institutions\, 100 professional society meetings and more than 150 radiology groups throughout the United States\, Canada and Europe. \nDate: October 27\, 2022\nTime: 3:30pm – 4:30pm EDT \nWho should attend? PET Interpreters\, Technologists\, Referring Physicians\, Marketers \nIn this session\, Dr. Bridwell will: \n\nidentify the role of FDG for staging\, restaging and response assessment\nexplain the role of FES for staging and restaging\nhelp you to understand the synergy of FES and FGD as a predictive diagnostic tool\n\nREGISTER NOW\nTHIS ACTIVITY IS APPROVED FOR CREDIT BY THE ASRT\nTo receive CE credit you must register individually\, attend the entire session and complete a post-webinar survey. Instructions regarding receiving CEH (1.0) will be provided at the conclusion of the session. Approved by ASRT Cat A 1.0 VAD00320015
URL:https://sofie.com/event/breast-cancer-pet-ct-applications-webinar/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230111T153000
DTEND;TZID=America/New_York:20230111T163000
DTSTAMP:20260408T180824
CREATED:20221213T003506Z
LAST-MODIFIED:20230103T172757Z
UID:2854-1673451000-1673454600@sofie.com
SUMMARY:Birth of a Radiopharmaceutical
DESCRIPTION:Presenter: Barbara J Grabher BS\, CNMT\, RT(N)\, NCT\, FSNMMI-TS\nManager\, Application Specialist and Product Technology for Life Molecular Imaging \nBarbara Grabher has been in the field of Nuclear Medicine for over 38 years\, she earned her Associates Degree in Nuclear Medicine from Delaware Technical and Community College in 1983 and earned her bachelor’s degree in Organizational Management from Wilmington University in 2018. She is board-certified by the American Registry of Radiologic Technologists and the Nuclear Medicine Technology Certification Board in both Nuclear Medicine and as a Nuclear Cardiology Technologist. Ms. Grabher received her Nuclear Medicine fellowship status by the SNMMI Technologist section in June 2021 being one of only 109 Nuclear Medicine technologist in the country to receive this recognition. She’s given presentations at the local level as well as nationally\, on topics related to both nuclear cardiology and neurology specializing in DaT imaging and movement disorders as well as amyloid imaging. She’s had 4 manuscripts published in the JNMT Technologist Journal on various topics. Ms. Grabher holds Six Sigma Greenbelt\, LEAN and Blackbelt Certificates specializing in Healthcare. She is a member of the Society of Nuclear Medicine Technologist Section and has affiliations that include the Society of Nuclear Medicine\, and the American Society of Radiologic Technologists. Ms. Grabher is currently a Clinical Applications Specialist for Life Molecular Imaging supporting the amyloid plaque imaging agent Neuraceq. \nDate: January 11\, 2023\nTime: 3:30pm EST \nRegister Now\n  \nWho should attend? PET Interpreters\, Technologists\, Referring Physicians\, Marketers \nIn this webinar\, Ms. Grabher will help you to: \n\nunderstand the complex process companies go through when getting a radiopharmaceutical FDA approved\nlist the different phases of clinical trials from bench to approval when getting a tracer FDA approved\nknow the different types of FDA Applications and Approvals there are\nrealize the amount of time\, money and resources companies use to hopefully get their tracer approved\nunderstand the importance of clinical trials and the need for diverse patient population participation
URL:https://sofie.com/event/birth-of-a-radiopharmaceutical/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230216
DTEND;VALUE=DATE:20230217
DTSTAMP:20260408T180824
CREATED:20230125T212447Z
LAST-MODIFIED:20230125T212928Z
UID:2881-1676505600-1676591999@sofie.com
SUMMARY:Northern California Chapter SNMMI Annual Meeting
DESCRIPTION:Visit SOFIE at the upcoming Northern California Chapter SNMMI Annual Meeting on February 16\, 2023 in Pleasanton\, CA.
URL:https://sofie.com/event/northern-california-chapter-snmmi-annual-meeting/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2023/01/Pleasanton2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230314
DTEND;VALUE=DATE:20230315
DTSTAMP:20260408T180824
CREATED:20230307T013251Z
LAST-MODIFIED:20230307T013715Z
UID:2954-1678752000-1678838399@sofie.com
SUMMARY:The Future of Radiopharmaceuticals: Targeted Theranostic Therapeutics (digital conference)
DESCRIPTION:Visit SOFIE at The Future of Radiopharmaceuticals: Targeted Theranostic Therapeutics (digital conference) on Tuesday\, March 14. \nDigital Conference\,\n8:00AM EST // 1:00PM GMT // 2:00PM CET \nThe Future of Radiopharmaceuticals: Targeted Theranostic Therapeutics (digital conference) \nSherly Mosessian\, Chief Scientific Officer of SOFIE is presenting: \nFibroblast Activation Protein (FAP) Inhibitors as Biomarkers in Oncology\, Fibrosis\, and Cardiovascular Disease\n\n\nCurrent state of FAP as a target for radioligand and non-radioligand interventions\nClinical development update on fluorine-18 and gallium-68 lead products targeting FAP\nFAPI as a companion diagnostic for patient selection and treatment monitoring in oncology\, fibrosis and cardiovascular disease\n\n\nRadiopharmaceuticals & Imaging\nTuesday\, 14 March 2023 11:05am – 11:35am\nEST (Eastern Standard Time\, GMT-5) \nLearn more
URL:https://sofie.com/event/the-future-of-radiopharmaceuticals-targeted-theranostic-therapeutics/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230614T153000
DTEND;TZID=America/New_York:20230614T163000
DTSTAMP:20260408T180824
CREATED:20230607T000935Z
LAST-MODIFIED:20230607T003559Z
UID:3019-1686756600-1686760200@sofie.com
SUMMARY:Current State of FAP Ligands for Diagnostic Use in Oncology
DESCRIPTION:Presenter: Dr. Sherly Mosessian earned her bachelors degree in Biochemistry\, followed by her Ph.D from UCLA Department of Molecular\, Medical Pharmacology\, with publications in tumor signaling\, molecular imaging targets and clinical trials of Position Emission Tomography (PET) probes. In her role as the Chief Scientific Officer of SOFIE she formulates the strategic plan for scientific objectives of the organization\, including leading the FAPI clinical development program. \nDate: June 14\, 2023\nTime: 3:30pm – 4:30pm EDT \nWho should attend? PET Interpreters\, Technologists\, Referring Physicians\, Marketers \nIn this session\, Dr. Mosessian will: \n\nexplain the significance of FAP as a target in oncology\nhighlight the progress made to date with FAP targeting ligands for diagnostic use in oncology\ndescribe the current clinical trials and regulatory landscape for FAP targeting ligands\n\nREGISTER NOW\nTHIS ACTIVITY IS APPROVED FOR CREDIT BY THE SNMMI
URL:https://sofie.com/event/current-state-of-fap-ligands-for-diagnostic-use-in-oncology/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260408T180824
CREATED:20230408T000103Z
LAST-MODIFIED:20230711T142322Z
UID:2986-1690243200-1690502399@sofie.com
SUMMARY:Targeted Radiopharmaceuticals Summit
DESCRIPTION:Sherly Mosessian\, PhD\, SOFIE’S Chief Scientific Officer\, is a featured speaker at the upcoming 2nd Annual Targeted Radiopharmaceuticals Summit US from July 25-27\, 2023 in Boston\, MA. \nMore details on the meeting here.
URL:https://sofie.com/event/targeted-radiopharmaceuticals-summit/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2023/04/Boston.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230824T153000
DTEND;TZID=America/New_York:20230824T163000
DTSTAMP:20260408T180824
CREATED:20230818T013242Z
LAST-MODIFIED:20230818T014412Z
UID:3090-1692891000-1692894600@sofie.com
SUMMARY:PET/CT Applications for GYN Malignancies
DESCRIPTION:Presenter: Dr. Robert Bridwell\, MD\, MBA\nMedical Advisor at SOFIE \nDr. Robert Bridwell\, medical advisor to SOFIE\, and co-founder of PETLinQ\, is a board-certified physician in both Internal Medicine and Nuclear Medicine. He has extensive knowledge and experience in continuous quality improvement programs for PET and PET/CT imaging\, utilizing physician empowerment training\, protocol development assistance\, and quality assurance guidelines. In the last five years\, Dr. Bridwell has been invited to make numerous presentations\, which have included more than 1200 hours of CME credit delivered to more than 350 institutions\, 100 professional society meetings and more than 150 radiology groups throughout the United States\, Canada and Europe. \nDate: August 24\, 2023\nTime: 3:30pm EDT \nRegister Now\nWho should attend? PET Interpreters\, Technologists\, Referring Physicians\, Marketers \nIn this webinar\, Dr. Bridwell will help you to: \n\nunderstand the use of FDG PET/CT for cervical cancer\nunderstand the use of FDG PET/CT for endometrial cancer\nunderstand the use of FDG PET/CT for ovarian cancer\ndiscuss the latest updates on FDG PET/CT for GYN malignancies
URL:https://sofie.com/event/pet-ct-applications-for-gyn-malignancies/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230905
DTEND;VALUE=DATE:20230910
DTSTAMP:20260408T180824
CREATED:20230818T014342Z
LAST-MODIFIED:20230818T014757Z
UID:3096-1693872000-1694303999@sofie.com
SUMMARY:2023 Annual World Molecular Imaging Congress
DESCRIPTION:Visit SOFIE at the upcoming 2023 Annual World Molecular Imaging Congress from September 5 – 9\, 2023 in Prague\, Czech Republic.
URL:https://sofie.com/event/2023-annual-world-molecular-imaging-congress/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2023/08/CzechRepublic.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230909
DTEND;VALUE=DATE:20230914
DTSTAMP:20260408T180824
CREATED:20230907T195831Z
LAST-MODIFIED:20230907T195831Z
UID:3165-1694217600-1694649599@sofie.com
SUMMARY:EANM 23
DESCRIPTION:Visit SOFIE at the upcoming EANM 2023 Congress from September 9 – 13\, 2023 in Vienna\, Austria.
URL:https://sofie.com/event/eanm-23/
ATTACH;FMTTYPE=image/png:https://sofie.com/wp-content/uploads/2023/09/EANM.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231012
DTEND;VALUE=DATE:20231014
DTSTAMP:20260408T180824
CREATED:20220907T192235Z
LAST-MODIFIED:20230818T015741Z
UID:2668-1697068800-1697241599@sofie.com
SUMMARY:3rd ICPO Forum for Theranostics in Precision Oncology
DESCRIPTION:After the great success of the 2nd ICPO FORUM we are delighted to announce that the 3rd ICPO Forum for Theranostics in Precision Oncology is taking place in Munich Garching from the 12-13 October 2023. \nWe would love to see you onsite on this occasion as we will gather specialists and partners from academia and industry in the field of Precision Oncology\, as well as patient advocates and representatives of non-profit associations coming\, from all over the world. The program under preparation will create a unique opportunity for you to: \n\nGrasp the latest trends on how to expand patient access to Theranostics in Precision Oncology\nExchange with colleagues from across the global ICPO Community\nEnjoy the stimulating program ranging from scientific innovation to patient outcomes\nConnect with ICPO partners during the industry exhibition and social functions
URL:https://sofie.com/event/3rd-icpo-forum-for-theranostics-in-precision-oncology/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/09/GarchingMunich.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231103
DTEND;VALUE=DATE:20231106
DTSTAMP:20260408T180824
CREATED:20220907T222221Z
LAST-MODIFIED:20230818T021613Z
UID:2675-1698969600-1699228799@sofie.com
SUMMARY:Western Region Society of Nuclear Medicine
DESCRIPTION:Visit SOFIE at the upcoming meeting from November 3 – 5\, 2023 in Vancouver\, BC.
URL:https://sofie.com/event/western-region-society-of-nuclear-medicine/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/09/Vancouver.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240118
DTEND;VALUE=DATE:20240120
DTSTAMP:20260408T180824
CREATED:20231210T232117Z
LAST-MODIFIED:20231210T232117Z
UID:3236-1705536000-1705708799@sofie.com
SUMMARY:PSMA PET Conference
DESCRIPTION:Visit SOFIE at the upcoming PSMA PET Conference: \nThursday\, January 18\, 2024 – Friday\, January 19\, 2024\nUCSF Mission Bay Conference Center\nRobertson Auditorium (2nd Floor)\n1675 Owens Street\nSan Francisco\, CA 94158
URL:https://sofie.com/event/psma-pet-conference/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2023/12/UCSF.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240322
DTEND;VALUE=DATE:20240324
DTSTAMP:20260408T180824
CREATED:20240208T155519Z
LAST-MODIFIED:20240208T155519Z
UID:2900-1711065600-1711238399@sofie.com
SUMMARY:New England Chapter Technologist Section
DESCRIPTION:Visit SOFIE at the upcoming New England Chapter of Nuclear Medicine and Molecular Imaging Technologist Section’s.\n​\n54th NECTS Spring Symposium\nMarch 22 – 23\, 2024 | Falmouth\, MA\n​\nSea Crest Beach Hotel\n350 Quaker Rd\nNorth Falmouth\, MA 02556\n​\nVOICE Credits: 14 CEUs Pending
URL:https://sofie.com/event/new-england-chapter-technologist-section/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2024/02/Falmouth.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240327T153000
DTEND;TZID=America/New_York:20240327T163000
DTSTAMP:20260408T180824
CREATED:20231210T233207Z
LAST-MODIFIED:20240310T214127Z
UID:3240-1711553400-1711557000@sofie.com
SUMMARY:The path from Diagnostic to Theragnostic
DESCRIPTION:Presenter: Ian Zolty\, CNMT\nMt. Sinai Hospital \nDate: March 27\, 2024\nTime: 3:30pm – 4:30pm EDT \nIan Zolty is a licensed nuclear medicine technologist and a radiology operations manager for the Mount Sinai Hospital and Icahn School of Medicine in New York city. He is also the isotope representative on the pharmaceutics and therapeutics committee. \nThroughout his career he has built and expanded diagnostic and therapeutic programs in hospital and private practice environments. Ian works both on provider and patient aspects of molecular imaging and therapy.  He has deep knowledge of supply chain\, contracting\, billing\, compliance\, and direct patient care as well as financial advocacy for patients. \nFollowing the lecture\, participants will be better able to: \n\ncontrast the differences between radiopharmaceuticals that are strictly diagnostic\, strictly therapeutic and applicable to theranostics\nsummarize the requirements for a safe and comprehensive theranostic program\nmanage the operational needs and business expectations in a robust theranostic program\n\n  \nRegister Now
URL:https://sofie.com/event/from-diagnostic-to-theragnostic/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240530T153000
DTEND;TZID=America/New_York:20240530T163000
DTSTAMP:20260408T180824
CREATED:20231210T233512Z
LAST-MODIFIED:20240514T232244Z
UID:3242-1717083000-1717086600@sofie.com
SUMMARY:Current state of FAP Targeting Radioligands
DESCRIPTION:Presenter: Sherly Mosessian\, Ph.D\nSOFIE Chief Scientific Officer\n\nDr. Mosessian earned her bachelors degree in Biochemistry\, followed by her Ph.D from UCLA Department of Molecular\, Medical Pharmacology\, with publications in tumor signaling\, molecular imaging targets and clinical trials of Position Emission Tomography (PET) probes. In her role as the Chief Scientific Officer of SOFIE she formulates the strategic plan for scientific objectives of the organization\, including leading the FAPI clinical development program. \nIn this session\, Dr. Mosessian will help you to understand the significance of FAP as a target for imaging and therapy\, highlight latest progress in FAP targeting for therapeutic use\, explain advancements made with FAP targeting radioligands in imaging\, and describe the clinical development and regulatory approval progress with FAP targeting radioligands \nRegister Now
URL:https://sofie.com/event/current-state-of-fap-targeting-radioligands/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240828T153000
DTEND;TZID=America/New_York:20240828T163000
DTSTAMP:20260408T180824
CREATED:20240819T231527Z
LAST-MODIFIED:20240819T231936Z
UID:3538-1724859000-1724862600@sofie.com
SUMMARY:Not Everything that Shines is Gold: False-Positive Findings on FDG PET/CT
DESCRIPTION:Presenter: Dr. Munir Ghesani\, MD\, FACNM\, FACR\, FSNMMI\nMedical Director of the United Theranostics\, Princeton and Chief Medical Officer of the United Theranostics \nDate: Wednesday\, August 28\, 2024\nTime: 3:30pm – 4:30pm EDT \nMunir Ghesani\, MD\, FACNM\, FACR\, FSNMMI is the Medical Director of the United Theranostics\, Princeton and Chief Medical Officer of the United Theranostics. Previously\, he has served as the Systems Chief of Nuclear Medicine and Molecular Imaging at the Mount Sinai Health\, New York. Dr. Ghesani has been actively involved in clinical practice\, research\, clinical trials and education for more than 25 years\, primarily focusing on nuclear medicine\, molecular imaging and targeted radiopharmaceutical therapies. \nDr. Ghesani has more than 200 publications in peer-reviewed journals and is the Editor-in-Chief of a three-part book on nuclear medicine and molecular imaging. He has given more than 150 presentations at regional\, national\, and international conferences. Dr. Ghesani has served in leadership roles in various societies and colleges\, including the Immediate Past President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)\, Past-President of the Education and Research Foundation of Nuclear Medicine and Molecular Imaging\, Past Chairman of the American Board of Nuclear Medicine\, Past Chairman of the Government Relations Committee and the FDA Task Force of the SNMMI and Past Chairman of the Nuclear Medicine and PET Accreditation Committee of the American College of Radiology. In January 2020\, he was awarded the ACNM Personal Best Mentor of the Year. He has been awarded as the Fellow of the American College of Nuclear Medicine (2006)\, the American College of Radiology (2018) and the Society of Nuclear Medicine and Molecular Imaging (2023). \nIn this session\, Dr. Ghesani will help you to: \n\nunderstand high sensitivity of PET portion of PET/CT\, providing excellent negative predictive value.\nunderstand how high negative predictive value in turn improves clinical outcomes.\nrecognize that all attempts should be made to improve the specificity to decrease the number of false-positives.\n\nApproved for 1.0 CE credit from SNMMI. \n  \nRegister Now
URL:https://sofie.com/event/not-everything-that-shines-is-gold-false-positive-findings-on-fdg-pet-ct/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241016T153000
DTEND;TZID=America/New_York:20241016T163000
DTSTAMP:20260408T180824
CREATED:20241010T182457Z
LAST-MODIFIED:20241010T183436Z
UID:3593-1729092600-1729096200@sofie.com
SUMMARY:Understanding Beta-amyloid\, Tau and the AD Cascade
DESCRIPTION:Presenter: Barbara J Grabher BS\, CNMT\, RT(N)\, NCT\, FSNMMI-TS\nSenior Clinical Applications Specialist: Life Molecular Imaging \nDate: Wednesday\, October 16\, 2024\nTime: 3:30pm – 4:30pm EDT \nBarbara Grabher has been in the field of Nuclear Medicine for over 38 years\, she earned her Associates Degree in Nuclear Medicine from Delaware Technical and Community College in 1983 and earned her bachelor’s degree in Organizational Management from Wilmington University in 2018. She is board-certified by the American Registry of Radiologic Technologists and the Nuclear Medicine Technology Certification Board in both Nuclear Medicine and as a Nuclear Cardiology Technologist. Ms. Grabher received her Nuclear Medicine fellowship status by the SNMMI Technologist section in June 2021 being one of only 109 Nuclear Medicine technologist in the country to receive this recognition. She’s given presentations at the local level as well as nationally\, on topics related to both nuclear cardiology and neurology specializing in DaT imaging and movement disorders as well as amyloid imaging. She’s had 4 manuscripts published in the JNMT Technologist Journal on various topics. Ms. Grabher holds Six Sigma Greenbelt\, LEAN and Blackbelt Certificates specializing in Healthcare. She is a member of the Society of Nuclear Medicine Technologist Section and has affiliations that include the Society of Nuclear Medicine\, and the American Society of Radiologic Technologists. Ms. Grabher is currently a Clinical Applications Specialist for Life Molecular Imaging supporting the amyloid plaque imaging agent Neuraceq®. \nIn this session\, Barb will help you to: \n• understand what β-amyloid neuritic plaques are and how they are formed \n• understand what neurofibrial tangles (Tau) are and how they are formed \n• explain the Alzheimer’s disease (AD) cascade \n• explain the AD spectrum \n• appreciate the importance of how and when molecular imaging is used \nApproved for 1.0 CEH credit from SNMMI. \n  \nRegister Now
URL:https://sofie.com/event/understanding-beta-amyloid-tau-and-the-ad-cascade/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241109
DTEND;VALUE=DATE:20241110
DTSTAMP:20260408T180824
CREATED:20241108T004928Z
LAST-MODIFIED:20241108T005022Z
UID:3617-1731110400-1731196799@sofie.com
SUMMARY:2024 ATAWM and CCSNMMI Michigan Road Show
DESCRIPTION:Visit SOFIE at the 2024 ATAWM and CCSNMMI Michigan Road Show– In Person at BAMF Health on November 9\, 2024 at the Doug Meijer Medical Innovation Building in Grand Rapids\, MI. \nCSO Sherly Mosessian\, Ph.D.\, will present a talk\, “Imaging Cancer through the Stroma- FAPI PET/CT\, a Novel Tracer in Oncology” \nClick here to view the schedule of events.
URL:https://sofie.com/event/2024-atawm-and-ccsnmmi-michigan-road-show/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2024/11/GrandRapids.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241109
DTEND;VALUE=DATE:20241110
DTSTAMP:20260408T180824
CREATED:20241010T195815Z
LAST-MODIFIED:20241010T195815Z
UID:3603-1731110400-1731196799@sofie.com
SUMMARY:EGL SNMMI Annual Meeting
DESCRIPTION:Visit SOFIE at the Eastern Great Lakes SNMMI Chapter Meeting on November 9\, 2024 at the Roswell Park Cancer Center in Buffalo\, NY. \nRegister today for the 2024 EGLSNMMI Annual Meeting
URL:https://sofie.com/event/egl-snmmi-annual-meeting/
ATTACH;FMTTYPE=image/png:https://sofie.com/wp-content/uploads/2024/10/EGLSNMMI.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250327T153000
DTEND;TZID=America/New_York:20250327T163000
DTSTAMP:20260408T180824
CREATED:20250311T170349Z
LAST-MODIFIED:20250311T170646Z
UID:3787-1743089400-1743093000@sofie.com
SUMMARY:Amyloid Biomarker Imaging and FDG in the Era of an Approved Anti Amyloid Therapy
DESCRIPTION:Presenter: Dr. Robert Bridwell\, MD\, MBA Medical Advisor at SOFIE Dr. Robert Bridwell\, medical advisor to SOFIE\, and co-founder of PETLinQ\, is a board-certified physician in both Internal Medicine and Nuclear Medicine. He has extensive knowledge and experience in continuous quality improvement programs for PET and PET/CT imaging\, utilizing physician empowerment training\, protocol development assistance\, and quality assurance guidelines. In the last five years\, Dr. Bridwell has been invited to make numerous presentations\, which have included more than 1200 hours of CME credit delivered to more than 350 institutions\, 100 professional society meetings and more than 150 radiology groups throughout the United States\, Canada and Europe. \nDate: March 27\, 2025\nTime: 3:30pm – 4:30pm EDT \nIn this session\, Dr. Bridwell will help you to: \n\nunderstand the role of imaging and CSF biomarkers to identify patients for anti amyloid therapy\nunderstand the role of Centiloid scoring to improve interpreter confidence as well as to follow patients on therapy\nunderstand the clinical management pathway for patients on anti amyloid therapy\nreview the pitfalls of imaging and interpretation\n\nTHIS ACTIVITY IS APPROVED FOR 1.0 CEH CREDIT BY SNMMI \nREGISTER NOW
URL:https://sofie.com/event/amyloid-biomarker-imaging-and-fdg-in-the-era-of-an-approved-anti-amyloid-therapy/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250412
DTEND;VALUE=DATE:20250414
DTSTAMP:20260408T180824
CREATED:20210521T174319Z
LAST-MODIFIED:20250129T010559Z
UID:1868-1744416000-1744588799@sofie.com
SUMMARY:Pacific Northwest Technologist Chapter
DESCRIPTION:Join SOFIE at the upcoming Viva Las Vegas Pacific Southwest Technologist Chapter meeting from April 12 – 13\, 2025 at the Renaissance Seattle\, Seattle\, WA.
URL:https://sofie.com/event/pacific-northwest-technologist-chapter/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2021/05/Seattle.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250512
DTEND;VALUE=DATE:20250517
DTSTAMP:20260408T180824
CREATED:20230125T214614Z
LAST-MODIFIED:20250224T161258Z
UID:2891-1747008000-1747439999@sofie.com
SUMMARY:PEGS Boston Summit
DESCRIPTION:Visit SOFIE at the upcoming PEGS Boston Summit from May 12 – 16\, 2025 in Boston\, MA. On Wednesday\, May 14\, SOFIE CSO Sherly Mosessian\, PhD\, will present on “[18F]FAPI-74 PET in Gastrointestinal Cancers – Addressing an Unmet Need”. \nPEGS Boston Summit website
URL:https://sofie.com/event/pegs-boston-summit/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2023/04/Boston.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250618T153000
DTEND;TZID=America/New_York:20250618T163000
DTSTAMP:20260408T180824
CREATED:20250602T165346Z
LAST-MODIFIED:20250602T165500Z
UID:3879-1750260600-1750264200@sofie.com
SUMMARY:Current State of FAP Targeting Radioligands In Oncology
DESCRIPTION:Presenter: Sherly Mosessian\, Ph.D\, SOFIE Chief Scientific Officer \nDate: Wednesday\, June 18\, 2025\nTime: 3:30pm – 4:30pm EDT \nDr. Mosessian earned her bachelors degree in Biochemistry\, followed by her Ph.D from UCLA Department of Molecular\, Medical Pharmacology\, with publications in tumor signaling\, molecular imaging targets and clinical trials of Position Emission Tomography (PET) probes. In her role as the Chief Scientific Officer of SOFIE she formulates the strategic plan for scientific objectives of the organization\, including leading the FAPI clinical development program. \nIn this session\, Dr. Mosessian will: \n\ndescribe the significance and potential of FAP as a target in oncology\nhighlight recent developments in clinical trials with FAP targeting in therapy\nhighlight recent developments in clinical trials with FAP targeting in imaging\ndescribe latest progress with FAPI academic global outreach program\n\nApproved for 1.0 CEH credit from SNMMI. \n  \nRegister Now
URL:https://sofie.com/event/current-state-of-fap-targeting-radioligands-in-oncology/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250827T153000
DTEND;TZID=America/New_York:20250827T163000
DTSTAMP:20260408T180824
CREATED:20250819T204335Z
LAST-MODIFIED:20250820T170839Z
UID:3969-1756308600-1756312200@sofie.com
SUMMARY:Advancing Cardiac PET MPI with Flyrcado™: Considerations for Clinical Practice
DESCRIPTION:Presenter: April Mann\, MBA\, CNMT\, NCT\, RT(N)\, MASNC\, FSNMMI-TS\, Cardiology KOL and Stakeholder Engagement Lead at GE HealthCare \nDate: Wednesday\, August 27\, 2025\nTime: 3:30pm – 4:30pm EDT \nMs. Mann is the Cardiology KOL and Stakeholder Engagement Lead at GE HealthCare. Prior to joining GE\, she was the VP\, Cardiology/Market Access at Ionetix Corporation. Before entering the industry sector in 2019\, she was employed by Hartford Healthcare since 1992\, and her roles have included System Manager\, Business Intelligence & Data Analytics and Quality for the Heart & Vascular Institute\, manager of the cardiac catheterization lab\, non-invasive cardiology\, nuclear cardiology\, nuclear medicine\, and vascular ultrasound imaging. She has been a nuclear medicine technologist since 1989 and has a BA in Healthcare Management and a Masters’\, Business Administration (MBA). Ms. Mann has been active within the nuclear medicine/ nuclear cardiology community serving as the President\, Society of Nuclear Medicine and Molecular Imaging-Technologist Section as well as chaired and served on numerous committees for the Society of Nuclear Medicine Technologist Section\, Society of Nuclear Medicine and the American Society of Nuclear Cardiology as well as served on the Boards of the Intersocietal Accreditation Commission\, Nuclear Medicine Technology Certification Board and the Education and Research Foundation. She has over 27 publications including book chapters\, continuing education and research manuscripts and has given over 250 presentations on various topics in nuclear medicine\, nuclear cardiology\, management\, quality and general cardiology topics throughout her career and is well respected in the Nuclear Medicine/Nuclear Cardiology community and have several years of leadership\, operations and business experience within the healthcare community. \nIn this session\, April will: \n\ndiscuss the imaging characteristics and benefits of FlyrcadoTM\ndiscuss patient preparation for FlyrcadoTM\ndiscuss FlyrcadoTM imaging protocols\ndiscuss processing and display considerations\nunderstand the technologist’s role in optimizing image acquisition\, reducing artifacts\, and ensuring accurate patient positioning for high-quality diagnostic outcomes\nidentify standards uptake patterns with various disease presentation\n\nApproved for 1.0 CEH credit from SNMMI. \n  \nRegister Now
URL:https://sofie.com/event/advancing-cardiac-pet-mpi-with-flyrcado-considerations-for-clinical-practice/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/10/Webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250904
DTEND;VALUE=DATE:20250908
DTSTAMP:20260408T180824
CREATED:20250906T202856Z
LAST-MODIFIED:20250906T205405Z
UID:4078-1756944000-1757289599@sofie.com
SUMMARY:ASNC 2025
DESCRIPTION:Visit SOFIE at the upcoming ASNC2025 Annual Scientific Session & Exhibition from September 4 – 7\, 2025 in Orlando\, FL.
URL:https://sofie.com/event/asnc-2025/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2022/09/Orlando.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250918
DTEND;VALUE=DATE:20250920
DTSTAMP:20260408T180824
CREATED:20250129T013627Z
LAST-MODIFIED:20250906T205337Z
UID:3743-1758153600-1758326399@sofie.com
SUMMARY:Jackson Laboratory Immuno-Cardiology Symposium
DESCRIPTION:SOFIE is proud to sponsor the upcoming Jackson Laboratory Immuno-Cardiology Symposium from September 18 – 19\, 2025 in Bar Harbor\, Maine.
URL:https://sofie.com/event/jackson-laboratory-immuno-cardiology-symposium/
ATTACH;FMTTYPE=image/jpeg:https://sofie.com/wp-content/uploads/2025/01/BarHarbor.jpg
END:VEVENT
END:VCALENDAR